Anika Therapeutics (ANIK) Free Cash Flow (2010 - 2026)

Anika Therapeutics (ANIK) has reported Free Cash Flow for 17 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 28.8% year-over-year to -$2.1 million in Q2 2026; TTM through Jun 2026 was $562000.0, a 205.05% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, up 287.13% from the prior year.
• Free Cash Flow was -$2.1 million for Q2 2026 at Anika Therapeutics, up from -$6.3 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $5.7 million in Q3 2023 and troughed at -$9.8 million in Q2 2023.
• A 5-year average of -$926166.7 and a median of -$1.8 million in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow plunged 949.3% in 2023 and soared 1350.55% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$2.0 million in 2022, then jumped by 187.79% to $1.8 million in 2023, then sank by 84.71% to $275000.0 in 2024, then soared by 1350.55% to $4.0 million in 2025, then slumped by 153.47% to -$2.1 million in 2026.
• The last three Free Cash Flow figures came in at -$2.1 million (Q2 2026), -$6.3 million (Q1 2026), and $4.0 million (Q4 2025), per Business Quant data.